Get the Stockscreener App
38.09
1.20%
0.45
Ultragenyx Pharmaceutical Inc stock is traded at $38.09, with a volume of 575.37K.
It is up +1.20% in the last 24 hours and down -1.55% over the past month.
See More
Previous Close:
$37.64
Open:
$37.45
24h Volume:
575.37K
Relative Volume:
0.73
Market Cap:
$3.28B
Revenue:
$522.75M
Net Income/Loss:
$-558.99M
P/E Ratio:
-5.8872
EPS:
-6.47
Net Cash Flow:
$-439.53M
1W Performance:
+6.72%
1M Performance:
-1.55%
6M Performance:
-29.23%
1Y Performance:
-13.14%
1-Day Range:
$36.92
$38.15
1-Week Range:
$34.63
$38.15
52-Week Range:
$29.59
$60.37
Ultragenyx Pharmaceutical Inc Stock (RARE) Company Profile
Name
Ultragenyx Pharmaceutical Inc
Sector
Industry
Phone
415-483-8800
Address
60 LEVERONI COURT, NOVATO, CA
Compare RARE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RARE
Ultragenyx Pharmaceutical Inc
|
38.09 | 3.28B | 522.75M | -558.99M | -439.53M | -6.47 |
|
VRTX
Vertex Pharmaceuticals Inc
|
493.84 | 122.76B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
602.64 | 61.38B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
614.76 | 36.37B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.56 | 30.12B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
244.90 | 24.70B | 3.81B | -644.79M | -669.77M | -6.24 |
Ultragenyx Pharmaceutical Inc Stock (RARE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-06-24 | Upgrade | Goldman | Neutral → Buy |
| Apr-22-24 | Initiated | RBC Capital Mkts | Outperform |
| Dec-08-23 | Initiated | Wells Fargo | Overweight |
| Jun-14-23 | Resumed | Credit Suisse | Outperform |
| Jun-06-23 | Upgrade | Evercore ISI | In-line → Outperform |
| Apr-26-23 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-18-23 | Resumed | Canaccord Genuity | Buy |
| Dec-30-22 | Resumed | H.C. Wainwright | Buy |
| Nov-03-22 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Oct-13-22 | Upgrade | Guggenheim | Neutral → Buy |
| Aug-01-22 | Downgrade | Evercore ISI | Outperform → In-line |
| Mar-16-22 | Upgrade | Credit Suisse | Neutral → Outperform |
| Feb-11-22 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-30-21 | Initiated | H.C. Wainwright | Buy |
| Aug-19-21 | Initiated | UBS | Sell |
| Jul-15-21 | Initiated | Guggenheim | Neutral |
| Jun-29-21 | Upgrade | BofA Securities | Neutral → Buy |
| Jun-04-21 | Resumed | Robert W. Baird | Neutral |
| May-06-21 | Upgrade | Citigroup | Neutral → Buy |
| May-06-21 | Upgrade | Evercore ISI | In-line → Outperform |
| Apr-26-21 | Resumed | Credit Suisse | Neutral |
| Mar-02-21 | Resumed | Stifel | Buy |
| Feb-12-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-07-20 | Downgrade | Wedbush | Outperform → Neutral |
| Nov-24-20 | Resumed | Evercore ISI | In-line |
| Nov-12-20 | Downgrade | BofA Securities | Buy → Neutral |
| Aug-02-19 | Resumed | Wedbush | Outperform |
| Mar-27-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Feb-22-19 | Resumed | Raymond James | Outperform |
| Jan-02-19 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Nov-08-18 | Upgrade | Citigroup | Sell → Neutral |
| Sep-10-18 | Initiated | Morgan Stanley | Equal-Weight |
| Jun-21-18 | Downgrade | Credit Suisse | Outperform → Neutral |
| May-11-18 | Upgrade | Barclays | Equal Weight → Overweight |
| May-10-18 | Initiated | Goldman | Neutral |
| Apr-18-18 | Upgrade | SunTrust | Hold → Buy |
| Mar-22-18 | Resumed | Piper Jaffray | Overweight |
| Feb-21-18 | Reiterated | Stifel | Buy |
| Jan-22-18 | Upgrade | Evercore ISI | In-line → Outperform |
| Jan-18-18 | Initiated | Credit Suisse | Outperform |
| Dec-05-17 | Reiterated | Barclays | Equal Weight |
| Dec-04-17 | Upgrade | Jefferies | Hold → Buy |
| Sep-14-17 | Upgrade | Wedbush | Neutral → Outperform |
View All
Ultragenyx Pharmaceutical Inc Stock (RARE) Latest News
Ultragenyx (RARE) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release - Nasdaq
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | RARE Stock News - GuruFocus
Ultragenyx Expands Team with 21 New Hires, Grants Nearly 37,000 Restricted Stock Units - Stock Titan
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
BofA Adjusts Price Target for Ultragenyx (RARE) Ahead of Q1 Earnings | RARE Stock News - GuruFocus
Kyowa Kirin and Ultragenyx Announce Crysvita® (burosumab) Receives Conditional Marketing Authorisation in Europe for the Treatment of X-Linked Hypophosphatemia in Children | Libero Quotidiano.it - Libero Quotidiano
Mucopolysaccharidosis (MPS) Treatment Market Generated - openPR.com
How did Emil Kakkis build Ultragenyx into an ultrarare-disease powerhouse? - The Business Journals
BofA Adjusts Price Target on Ultragenyx Pharmaceutical to $80 From $83, Keeps Buy Rating - marketscreener.com
Ultragenyx: Commercial Engine Fuels Rare Disease Pipeline (NASDAQ:RARE) - Seeking Alpha
Roche's castoff Angelman drug gets second life in Oak Hill deal - FirstWord Pharma
Ultragenyx Pharmaceutical (RARE): Among Billionaire Stanley Druckenmiller’s Top Stock Picks with Huge Upside Potential - MSN
Ultragenyx (RARE) Soars 9.2%: Is Further Upside Left in the Stock? - Yahoo Finance
X-linked Hypophosphatemia Market Future Business - openPR.com
Ultragenyx Pharmaceutical (NASDAQ:RARE) Is Carrying A Fair Bit Of Debt - simplywall.st
Ultragenyx stock hits 52-week low at $33.37 amid market challenges - Investing.com Canada
Ultragenyx stock hits 52-week low at $33.37 amid market challenges By Investing.com - Investing.com South Africa
How another firm's FDA approval could mean a big win for Denali TherapeuticsSan Francisco Business Times - The Business Journals
Winners and wishers: 9 potential Bay Area drug approvals coming this yearSan Francisco Business Times - The Business Journals
Ultragenyx Pharmaceutical (NASDAQ:RARE) Hits New 52-Week LowShould You Sell? - MarketBeat
11 Best Gene Therapy Stocks to Buy According to Analysts - Insider Monkey
Why Ultragenyx Pharmaceutical (RARE) Is Among the Best Mid Cap Biotech Stocks to Buy - Insider Monkey
Ultragenyx Stays On JPMorgan's Focus List As Analyst Highlights Strong Long-Term Positioning - Benzinga
Ultragenyx price target raised to $117 from $104 at JPMorgan - TipRanks
Ultragenyx stock hits 52-week low at $36.99 amid market challenges - Investing.com Australia
Ultragenyx stock hits 52-week low at $36.99 amid market challenges By Investing.com - Investing.com South Africa
Strategic Move: Ultragenyx CCO Erik Harris to Drive Rezolute's Rare Disease Commercialization - Stock Titan
Ultragenyx CEO Emil Kakkis: ‘Our Future Is In Our Hands’ - insights.citeline.com
Can UX111 Script History As The First FDA-Approved Treatment For Sanfilippo Syndrome Type A? - RTTNews
Ultragenyx (RARE) Aligns With FDA on Phase III Neuro Study Plans - MSN
Ultragenyx Strengthens Team with Strategic RSU Grants Worth Millions - StockTitan
Ultragenyx price target lowered to $115 from $140 at Piper Sandler - Yahoo Finance
Piper Sandler cuts Ultragenyx stock target to $115; keeps overweight By Investing.com - Investing.com Canada
Demystifying Ultragenyx Pharmaceutical: Insights From 10 Analyst Reviews - Benzinga
Piper Sandler cuts Ultragenyx stock target to $115; keeps overweight - Investing.com
Opinion: Angelman Syndrome Race Heats Up Among Ionis, Ultragenyx and Neuren - BioSpace
Trending Report on X-linked Hypophosphatemia Market 2025-2032 - openPR
Have Insiders Sold Ultragenyx Pharmaceutical Shares Recently? - Simply Wall St
Ultragenyx Pharmaceutical Inc Stock (RARE) Financials Data
Revenue
Net Income
Cash Flow
EPS
Ultragenyx Pharmaceutical Inc Stock (RARE) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Kassberg Thomas Richard | CBO & EVP |
Mar 03 '25 |
Sale |
42.10 |
6,028 |
253,779 |
265,238 |
| Parschauer Karah Herdman | EVP and Chief Legal Officer |
Mar 03 '25 |
Sale |
42.10 |
12,846 |
540,817 |
75,287 |
| Crombez Eric | EVP and Chief Medical Officer |
Mar 03 '25 |
Sale |
42.10 |
8,945 |
376,584 |
71,922 |
| Pinion John Richard | See Remarks |
Mar 03 '25 |
Sale |
42.10 |
14,439 |
607,882 |
107,766 |
| KAKKIS EMIL D | President & CEO |
Mar 03 '25 |
Sale |
42.10 |
73,434 |
3,091,571 |
641,731 |
| KAKKIS EMIL D | President & CEO |
Feb 28 '25 |
Sale |
42.48 |
25,000 |
1,062,000 |
2,158,985 |
| Harris Erik | EVP & Chief Commercial Officer |
Mar 03 '25 |
Sale |
42.10 |
15,103 |
635,836 |
87,855 |
| Huizenga Theodore Alan | SVP, Chief Accounting Officer |
Mar 03 '25 |
Sale |
42.10 |
967 |
40,711 |
50,265 |
| Parschauer Karah Herdman | EVP and Chief Legal Officer |
Feb 27 '25 |
Sale |
42.88 |
2,990 |
128,224 |
54,991 |
0.24%
36.06%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):